Ranbaxy's Globalization Strategies and its Foray Into the US
|
|
ICMR HOME | Case Studies Collection
To download Ranbaxy's Globalization Strategies and its Foray Into the US case study
(Case Code: BSTR188) click on the button below, and select the case from the list of available cases:
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Case Studies by Area
» Case Studies by Industry
» Case Studies by Company
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
|
Case Details: |
Price: |
| Case Code |
: |
BSTR188 |
For delivery in electronic format: Rs. 400;
For delivery through courier (within India): Rs. 400 + Rs. 25 for Shipping & Handling Charges
ThemesInternational Business |
Growth and Challenges
|
| Case Length |
: |
17 Pages |
| Period |
: |
1995-2005 |
| Organization |
: |
Ranbaxy |
| Pub Date |
: |
2005 |
| Teaching Note |
: |
Not Available |
| Countries
|
: |
US, India |
| Industry |
: |
Pharma and Biotech |
Abstract:
|
The case discusses the globalization efforts of Ranbaxy Laboratories (Ranbaxy),
a leading pharma company in India. Ranbaxy started off distributing drugs in
foreign countries and went on to play a major role in the global generics
market. By 2004, the company had manufacturing plants in 10 locations,
ground operations in 45 countries and its products were sold in 70 countries
across the world. The case describes Ranbaxy's foray in the US markets where
it made a slow entry and adopted the route of Para IV filings to challenge
the supremacy of big pharma companies. By the first quarter of 2005,
Ranbaxy's sales in the US decreased by US$ 25 million, which was attributed
to severe price erosion in these markets due to increasing competition among
the US generics. The case describes the challenges facing the company in the
US and examines Ranbaxy's growth strategy for the US markets.
|
|
Issues:
» Entry and expansion strategies of Ranbaxy in foreign markets
» Growth initiatives of Ranbaxy in the US
» Challenges faced by Ranbaxy in the US
Contents:
Keywords:
Ranbaxy Labs, Globalization, Global Acquisitions, Patents Claim, Lipitor,
Generic Drugs, Patent Protection, Research and Development, Active
Pharmaceutical Ingredient, Ranbaxy-Pfizer Dispute
Ranbaxy's Globalization Strategies and its Foray Into the US
- Next Page>>
|
|
